---
title: "Living with Cognitively Unimpaired Alzheimer's Disease: Insights into Preclinical Experiences"
id: "stat-news-3-opinion-what-it-s-like-to-live-with-cognitively-unimpaired-alzheimer-s-disease"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-3-opinion-what-it-s-like-to-live-with-cognitively-unimpaired-alzheimer-s-disease"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/11/06/pre-clinical-alzheimers-disease-biomarkers-tests-mental-health/?utm_campaign=rss"
published_at: "2026-11-06T09:30:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Living with Cognitively Unimpaired Alzheimer's Disease: Insights into Preclinical Experiences
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-3-opinion-what-it-s-like-to-live-with-cognitively-unimpaired-alzheimer-s-disease
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/11/06/pre-clinical-alzheimers-disease-biomarkers-tests-mental-health/?utm_campaign=rss)
- **Published At:** 2026-11-06T09:30:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Patients with asymptomatic Alzheimer's disease display emotional and cognitive changes. - Research focuses on individuals with elevated amyloid levels. - Studies reveal these individuals experience different perspectives on memory and risk. - Noteworthy ongoing clinical trials are testing treatments for preclinical Alzheimer’s. - The emotional impact of test results varies between elevated and not elevated groups. - Educational efforts are essential for understanding risk and managing anxiety. - The initial findings may reshape dementia care practices in the future.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/11/06/pre-clinical-alzheimers-disease-biomarkers-tests-mental-health/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/11/06/pre-clinical-alzheimers-disease-biomarkers-tests-mental-health/?utm_campaign=rss) [research](https://www.statnews.com/topic/research/) [chronic disease](https://www.statnews.com/topic/chronic-disease/) [rare diseases](https://www.statnews.com/topic/rare-diseases/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [Midterms 2026](https://www.statnews.com/midterms-2026-health-care-policy-issues/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) My Account * [Settings](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing History](https://www.statnews.com/my-account/billing/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) * [Science, Shattered](https://www.statnews.com/american-science-shattered/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Wunderkinds 2026](https://www.statnews.com/wunderkinds/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) Opinion[Neurotransmissions](https://www.statnews.com/category/neurotransmissions-first-opinion-column-jason-karlawish/) # What it’s like to live with cognitively unimpaired Alzheimer’s disease ## Being diagnosed with ‘pre-clinical’ Alzheimer’s feels awfully clinical, people say * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/11/06/pre-clinical-alzheimers-disease-biomarkers-tests-mental-health/?utm_campaign=rss) ![](https://www.statnews.com/wp-content/uploads/2025/09/Neurotransmissions_Illustration_MollyFerguson_091925-645x645.jpg) Molly Ferguson for STAT By Jason Karlawish Nov. 6, 2026 Karlawish is a professor of medicine, medical ethics, health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine, co-director of the Penn Memory Center, and executive producer of the “Age of Aging” podcast. He writes [Neurotransmissions](https://www.statnews.com/category/neurotransmissions-first-opinion-column-jason-karlawish/), a STAT column about the new era of dementia. What is it like to have asymptomatic Alzheimer’s disease? The answer’s obvious, isn’t it? It is like nothing. It’s a silly question, really. How could living without symptoms — the vexing troubles with concentration, word finding, recalling new facts, the loss of a mental map — be an experience of something? Advertisement Like most short and simple answers, particularly when the subject is Alzheimer’s, the obvious answer’s wrong. For several years I’ve studied the experiences of people living with what someday may be called asymptomatic or cognitively unimpaired Alzheimer’s disease. Much of this work involves talking to people who have neither dementia nor mild cognitive impairment (MCI), but they do have evidence of Alzheimer’s disease pathology. I focused on people who learned their amyloid PET scan shows “elevated amyloid.” My research colleagues call them “biomarker positive” and categorize them as having “pre-clinical Alzheimer’s disease.” I’m not ready to diagnose and label them as patients. Not quite because I’m waiting on the results of my colleagues’ studies, whose results could both validate this new stage of Alzheimer’s disease and discover a treatment for it. (I’ll say more about these studies later.) Advertisement The key discovery my colleagues and I have made is that though these people may be asymptomatic, they do have a disease experience. Though they aren’t ill, compared to before they learned their amyloid biomarker result, they feel different. These feelings are animated by changes in how they interpret memory lapses, ponder present and future options, and relate to other people, especially family, friends, and co-workers. As one woman who learned she had elevated amyloid explained to me, “It’s less about medical than about my personality. A colonoscopy isn’t going to change who I am. This is my brain involved.” This is the first of two essays on what life is like living at biomarker-defined risk of dementia. First, permit me to set the stage. ## From the bedside to the desktop In the late 20th century, we saw the rise of what I call [desktop medicine](http://jama.ama-assn.org/cgi/content/full/304/18/2061). The desktop, with its fast networked computer, is where researchers discover these diseases and where physicians and patients go to find information to diagnose and treat them. Some examples of desktop diseases are hypertension, diabetes, hypercholesterolemia, and osteoporosis. Related Story ![](https://www.statnews.com/wp-content/uploads/2026/08/C0508954-Tau_protein_clusters_TEM-768x432.jpg) ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [STAT Plus: Study reveals new role for tau, a top target for Alzheimer’s drug development](https://www.statnews.com/2026/08/06/research-finds-how-tau-targets-cells-structure-alzheimers-drug-development/) This is very different from my practice at the Penn Memory Center, which follows a “bedside medicine” model. The foundation of bedside medicine is talking. I begin with a patient’s chief complaint — _My memory is failing_ — and then take a history of their illness experience, followed by an exam and cognitive testing. I then transform this information into a personalized case of the natural history of disease — for example, a diagnosis of dementia caused by Alzheimer’s disease. This practice is essentially the same as what physician [Alois Alzheimer](https://www.alzint.org/about/dementia-facts-figures/types-of-dementia/alzheimers-disease/alois-alzheimer/) was doing at the beginning of the 20th century. Unlike bedside diseases, desktop diseases are not defined by a person’s signs and symptoms. (Hypertension has been called “the silent killer.”) Instead, they’re defined by numbers. Their treatments don’t relieve present disability — instead, they reduce the risk of those events happening in the future. Finally, whereas bedside diseases are discovered by the joint work of clinicians and pathologists, desktop diseases are discovered and diagnosed through the joint work of clinical trialists and actuaries. Advertisement The trialist designs controlled, randomized, blinded experiments to test a drug in people with pathophysiological risk factors, such as elevated low-density lipoprotein, or LDL. If the trial shows the drug performs better than control (for example, fewer heart attacks) then the risk factor becomes a marker of disease and the actuaries step in. They tease apart the data to determine what cutoffs on the markers determine a person is at sufficient risk to take the drug. I call this clinical-actuarial correlation. In clinical practice, my colleagues call clinical-actuarial correlation “running the numbers,” and when a desktop disease is discovered, actuaries and web designers are eager to provide us with numbers. Cardiac disease, for example, has been an actuarial delight (see [here](https://professional.heart.org/en/guidelines-and-statements/prevent-calculator) and [here](https://tools.acc.org/cvd-risk-estimator-plus/#!/calculate/estimate/) and [here](https://www.paho.org/cardioapp/web/#/description)). Possibly quite soon, depending on the results of ongoing clinical trials in cognitively unimpaired people, dementia care will go desktop. ## Waiting on the studies There are, at present, three ongoing trials testing anti-amyloid drugs in cognitively unimpaired “biomarker positive” people. Notably, in the coming months, one of these trials — [Lilly’s Trailblazer 3](https://clinicaltrials.gov/study/NCT04437511) testing donanemab — will conclude. Like the other trials ([Eisai’s AHEAD](https://clinicaltrials.gov/study/NCT04468659) testing lecanemab, and [Roche’s PREVENtron](https://clinicaltrials.gov/study/NCT07717411) testing trontinemab), the therapeutic goal is to discover whether lowering amyloid will slow the transition from being a person who is cognitively unimpaired to a person living with dementia. Simply put, a positive trial will achieve two interrelated goals: validate a stage of disease before dementia or MCI, and discover treatment for that same stage. When that happens, I’ll start running the numbers on my patients’ brains. Much of what I’ve learned about what this will be like comes from people who participated in one of the earliest of these preclinical anti-amyloid trials. The [A4 study](https://www.nejm.org/doi/full/10.1056/NEJMoa2305032) tested Lilly’s solanezumab against a placebo. Although solanezumab was unsuccessful, A4 established a foundation for the three ongoing trials. My colleagues and I interviewed 50 people who learned they had elevated amyloid and, for comparison, 30 who learned a “not elevated” result and therefore could not enroll in A4. Advertisement [ You’re reading Neurotransmissions by Jason Karlawish, a STAT+ column covering the new era in dementia diagnosis, treatment, and care. View all Neurotransmissions columns. ](https://www.statnews.com/category/neurotransmissions-first-opinion-column-jason-karlawish/) We called our study [SOKRATES](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0229137), for the Study of Knowledge and Reactions to Amyloid Testing — a fitting acronym, I think, as it gestures to the philosopher who declared that, despite the threat of death, the unexamined life is not worth living. To protect confidentiality, the quotes you’ll read are stripped of identifying information except for basic descriptive information on age and gender and bits of biography. ## Nine or 9,000 amyloids Among the people who learned an elevated amyloid result, the feeling of some degree of elevated risk of developing dementia was nearly uniform. A 78-year-old man explained, “I’ve a higher risk than most people to get Alzheimer’s, but it doesn’t mean I will get it.” In contrast, people who received a “not elevated result” demonstrated varying understandings of what that meant. In both groups, however, two notable but potentially correctable misunderstandings emerged. First, some people’s risk assessments were arguably off, especially the people with a not elevated result who concluded they would never get Alzheimer’s or had altogether eliminated the possibility of dementia from their future, neglecting that other diseases such as Lewy Body disease and LATE. The correction here, of course, is education about probability and the other diseases that cause dementia. The second problem was seen in both groups, and it amplified a common challenge with diagnosing desktop diseases. Patients and doctors alike struggle with ambiguity and uncertainty. Remember, in A4, their amyloid PET result wasn’t a number but instead one of two categories: “elevated” or “not elevated.” This categorical, qualitative information was frustrating, as this 68-year-old woman explained: “I asked the doctor, I said, ‘OK, how many amyloids? Are we talking nine amyloids or 9,000 amyloids?” People wanted the norm for amyloid and whether their result showed twice as many or three times as many. Others wondered if they were low, medium, or high. These sentiments from people whose health is typically writ by numbers — blood pressure, PSA, A1c, calcium scores, etc. — are understandable. Advertisement Related Story ![](https://www.statnews.com/wp-content/uploads/2026/07/AdobeStock_607797255-768x432.jpeg) ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [STAT Plus: Biogen Alzheimer’s drug slowed decline at rates on par with approved therapies, study shows](https://www.statnews.com/2026/07/14/biogen-alzheimers-tau-diranersen-trial-results-ionis-aaic/) The point is, as pathology is to bedside medicine, numbers are to desktop medicine. People want three metric measures: what’s my number, how does my number fit along the range of possible results, and how does it translate into my personal risk. A desktop diagnosis that falls short on any one of these three features may still be fit for practice, but it will likely cause patients frustration (“Do I have nine or 9,000 amyloids?”). For Alzheimer’s disease, the answer to “what’s my number?” is doubly challenging. Challenging because the field is working through which biomarker test or tests, what cutoffs, and what risk calculators will define cognitively unimpaired Alzheimer’s disease. Doubly because the tests and calculators are all intellectual property. There’s money to be made. Or not. ## ‘I worry a little bit more’ A feeling of being at risk can change a person. People who learned of an elevated amyloid result remained cognitively unimpaired, but for some, the knowledge changed how they felt about their memory. A 67-year-old man explained that before the test he worried when he forgot things, but after, he worried more. “You think, ‘OK, is this the beginning of Alzheimer’s?’” He, like others, noted, “To know [the amyloid is] up there maybe just kind of reinforces a little bit the possibility that it could be Alzheimer’s related.” Knowledge of elevated amyloid was an impactful event. We measured this with the Impact of Events Scale, which asks questions such as “I had waves of strong feelings about it” and “I thought about it when I didn’t mean to.” Two to three days after learning an amyloid PET result, the elevated amyloid group showed [notable increases in scores](https://jamanetwork.com/journals/jamaneurology/fullarticle/2769022?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jamaneurol.2020.2734) compared with the not-elevated group. As a clinician, I’m attentive to the fact that scores were particularly elevated in younger people, women, or those reporting memory problems, suggesting patients who need particular attention to their well-being. Notably, these feelings didn’t translate into symptoms of catastrophic mental illness, such as depression, unremitting anxiety, or suicide. This at least in part reflects the meticulous process of education and assessments of mood and well-being that preceded the PET scan. People who failed to understand the test, or who reported signs of significant depression, anxiety, or plans of self-harm weren’t tested. Instead, they were offered treatment for their mood disorder. Advertisement For people who learned a not elevated result, one word summed up how they felt about the knowledge of reduced risk: _relief_. We saw that word repeatedly in their interviews. A 70-year-old man with a notable family history of Alzheime
## Related Clinical Research

- [Diet and Alzheimer’s risk: Why no single best diet fits everyone](https://medichelpline.com/clinical-feed/medical-news-today-0-is-there-a-best-diet-to-help-lower-alzheimer-s-risk.md)
- [Avoiding smoking, diabetes, and high blood pressure in midlife may add up to 13 dementia-free years](https://medichelpline.com/clinical-feed/medical-news-today-0-avoiding-3-risk-factors-in-midlife-could-add-13-dementia-free-years.md)
- [Can AI chatbots help men talk about mental health?](https://medichelpline.com/clinical-feed/stat-news-3-ai-chatbots-aren-t-therapists-but-can-they-finally-get-men-to-open-up.md)
- [Four-stage framework for women’s heart health links adolescence through postmenopause](https://medichelpline.com/clinical-feed/stat-news-0-the-4-stages-of-women-s-heart-health-experts-present-new-framework.md)
- [PMOS/PCOS and Risk Signals for Alzheimer’s Disease and Dementia: Evidence Review](https://medichelpline.com/clinical-feed/endocrine-news-0-could-pmos-pcos-be-linked-to-alzheimer-s-disease-and-dementia.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.